Utilization and effect of neuromuscular blockade in a randomized trial of high-frequency oscillation.
Center-level variation
High-frequency oscillatory ventilation
Mediation analysis
Neuromuscular blocker
Secondary analysis of randomized controlled trial
Journal
Journal of critical care
ISSN: 1557-8615
Titre abrégé: J Crit Care
Pays: United States
ID NLM: 8610642
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
14
04
2021
revised:
08
08
2021
accepted:
10
08
2021
pubmed:
3
9
2021
medline:
28
10
2021
entrez:
2
9
2021
Statut:
ppublish
Résumé
We evaluated characteristics associated with neuromuscular blockade (NMB) use, center-level variation, and whether NMB mediated excess mortality among patients assigned to high-frequency oscillatory ventilation (HFOV) in the OSCILLATE trial. NMB exposure was defined as receipt after randomization; the primary outcome was hospital mortality. Descriptive analyses compared NMB-exposed vs unexposed patients. Multivariable analyses included patients not on baseline NMB. Cox regression evaluated associations of patient- and center-level variables with NMB use. A log-normal frailty model evaluated center effects. Mediation analysis examined the effect of NMB in HFOV-assigned patients. 376/548 patients (39 centers) received post-randomization NMB, of whom 165 received baseline NMB. Patients receiving post-randomization NMB (vs. not) had worse lung mechanics and gas exchange, received more sedation and vasopressors (p < 0.05), and had higher hospital mortality (44% vs. 34%, p = 0.03). Mean airway pressure ≥ 24 cmH In OSCILLATE, receipt of post-randomization NMB was associated with worse outcomes, but NMB use did not mediate HFOV-associated higher mortality.
Identifiants
pubmed: 34474282
pii: S0883-9441(21)00178-7
doi: 10.1016/j.jcrc.2021.08.006
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-92Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no conflicts of interest or applicable financial disclosures.